April 21 (Reuters) - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met the main goal of a late-stage ...

Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.

FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks ...

A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare ...

AstraZeneca said on Monday its ‌experimental treatment tozorakimab showed a "meaningful reduction" in moderate-to-severe ...

The combination showed a trend towards improved overall survival compared with TACE alone.

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...

Speaking to German newspaper Handelsblatt, CEO Pascal Soriot said proposed cost-cutting measures in the country’s healthcare ...